Read twice and referred to the Committee on Finance.
The bill bars federal health programs (HHS, VA, DoD, and other federal programs) from purchasing drugs whose active pharmaceutical ingredients (APIs) are manufactured in the People’s Republic of China, phased in: 60% non-China API sourcing by January 1, 2028, and 100% by January 1, 2030, with limited waivers until January 1, 2031. It requires drug labeling to disclose country of origin for each active ingredient.
Liberals worry tax breaks favor corporations over workers and access
Relative to its intended legislative type, this bill is a substantive statutory package that combines procurement prohibitions, a labeling amendment, and a temporary tax incentive.
The bill bars federal health programs (HHS, VA, DoD, and other federal programs) from purchasing drugs whose active pharmaceutical ingredients (APIs) are manufactured in the People’s Republic of China, phased in: 60% non-China API sourcing by January 1, 2028, and 100% by January 1, 2030, with limited waivers until January 1, 2031.
It requires drug labeling to disclose country of origin for each active ingredient.
It also provides a temporary 100% bonus depreciation (immediate expensing) for U.S. pharmaceutical and medical device manufacturing property placed in service from 2025 through 2030 to incentivize domestic production.
Controversial foreign-targeted sourcing rules plus tax cost and implementation complexity reduce chances despite bipartisan national-security arguments.
Relative to its intended legislative type, this bill is a substantive statutory package that combines procurement prohibitions, a labeling amendment, and a temporary tax incentive. It contains concrete deadlines and identifies responsible entities, but key implementation details and fiscal integration are underdeveloped.
Liberals worry tax breaks favor corporations over workers and access
These are examples from the analysis, not a ranked list of the most-affected groups.
Liberals worry tax breaks favor corporations over workers and access
Generally supportive of strengthening domestic drug supply chains and transparency to protect public health.
Concerned the bill relies on corporate tax breaks rather than direct public investment, and that rapid sourcing shifts could raise drug prices or cause shortages.
Wants guarantees for access, labor standards, and safeguards for low-income patients.
Views the bill as a pragmatic attempt to diversify and secure drug supply chains while incentivizing domestic production.
Sees the phased approach and waivers as reasonable but worries about implementation details, fiscal impacts, and possible short-term supply disruptions.
Would seek oversight, cost estimates, and contingency measures to avoid harming beneficiaries.
Favorable overall as a national-security and economic sovereignty measure limiting reliance on China.
Appreciates tax incentives that encourage private investment in U.S. manufacturing.
Might critique any excessive regulatory or procurement micromanagement, but generally supports restricting purchases tied to a geopolitical rival.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Controversial foreign-targeted sourcing rules plus tax cost and implementation complexity reduce chances despite bipartisan national-security arguments.
The bill has not accumulated any surfaced votes yet.
Liberals worry tax breaks favor corporations over workers and access
Controversial foreign-targeted sourcing rules plus tax cost and implementation complexity reduce chances despite bipartisan national-securi…
Relative to its intended legislative type, this bill is a substantive statutory package that combines procurement prohibitions, a labeling amendment, and a temporary tax incentive. It contains concrete deadlines and ide…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.